Dorothy Hodgkin Lecture 2012 Non-alcoholic fatty liver disease, insulin resistance and ectopic fat: A new problem in diabetes management

Diabetic Medicine

Volumn 29, Issue 9, 2012, Pages 1098-1107

  Byrne, C D ^a  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Insulin resistance; Non alcoholic steatohepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; POLYUNSATURATED FATTY ACID; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; BODY MASS; CARBOHYDRATE INTAKE; CARDIOVASCULAR DISEASE; CASE REPORT; CHOLESTEROL BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; ECHOGRAPHY; FAT INTAKE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERLIPIDEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; JOB STRESS; LIPID OXIDATION; LIPID STORAGE; LIVER FUNCTION TEST; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBESITY; REVIEW; SEDENTARY LIFESTYLE; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; UNITED KINGDOM; WAIST CIRCUMFERENCE; WEIGHT GAIN;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DIET, REDUCING; DISEASE MANAGEMENT; EXERCISE; FATTY LIVER; HUMANS; INSULIN RESISTANCE; LIFE STYLE; OBESITY; RISK FACTORS;

EID: 84865120793     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2012.03732.x     Document Type: Review

References (65)

1. Scorletti E, Calder PC, Byrne CD. Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments. Endocrine 2011; 40: 332-343.
2. Byrne CD, Olufadi R, Bruce KD, Cagampang FR, Ahmed MH. Metabolic disturbances in non-alcoholic fatty liver disease. Clin Sci (Lond) 2009; 116: 539-564.
3. Bhatia LS, Curzen NP, Calder PC, Byrne CD. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J 2012; 33: 1190-1200.
4. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363: 1341-1350.
5. Sattar N, Scherbakova O, Ford I, O'Reilly DS, Stanley A, Forrest E et al. Elevated alanine aminotransferase predicts new-onset type2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the West of Scotland Coronary Prevention Study. Diabetes 2004; 53: 2855-2860.
6. Ghouri N, Preiss D, Sattar N. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. Hepatology 2010; 52: 1156-1161.
7. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-873.
8. Targher G, Bertolini L, Padovani R, Rodella S, Zoppini G, Pichiri I et al. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type1 diabetes. J Hepatol 2010; 53: 713-718.
9. Holt HB, Wild SH, Wood PJ, Zhang J, Darekar AA, Dewbury K et al. Non-esterified fatty acid concentrations are independently associated with hepatic steatosis in obese subjects. Diabetologia 2006; 49: 141-148.
10. Hodson L, Frayn KN. Hepatic fatty acid partitioning. Curr Opin Lipidol 2011; 22: 216-224.
11. Byrne CD, Wareham NJ, Day NE, McLeish R, Williams DRR, Hales CN. Decreased non esterified fatty acid suppression and features of the insulin resistance syndrome occur in a sub-group of individuals with normal glucose tolerance. Diabetologia 1995; 38: 1358-1366.
12. Byrne CD, Wareham NJ, Brown DC, Clark PM, Cox LJ, Day NE et al. Hypertriglyceridaemia in subjects with normal and abnormal glucose tolerance: relative contributions of insulin secretion, insulin resistance and suppression of plasma non-esterified fatty acids. Diabetologia 1994; 37: 889-896.
13. Bruce KD, Byrne CD. The metabolic syndrome: common origins of a multifactorial disorder. Postgrad Med J 2009; 85: 614-621.
14. Bruce KD, Cagampang FR, Argenton M, Zhang J, Ethirajan PL, Burdge GC et al. Maternal high-fat feeding primes steatohepatitis in adult mice offspring, involving mitochondrial dysfunction and altered lipogenesis gene expression. Hepatology 2009; 50: 1796-1808.
15. Basciano H, Miller AE, Naples M, Baker C, Kohen R, Xu E et al. Metabolic effects of dietary cholesterol in an animal model of insulin resistance and hepatic steatosis. Am J Physiol Endocrinol Metab 2009; 297: E462-E473.
16. Kleiner DE, Brunt EM, Van NM, Behling C, Contos MJ, Cummings OW et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
17. Guha IN, Parkes J, Roderick PR, Harris S, Rosenberg WM. Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease. Gut 2006; 55: 1650-1660.
18. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004; 127: 1704-1713.
19. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-854.
20. Ahmed MH BC. Non-alcoholic steatatohepatitis and metabolic syndrome. In: Byrne C, Wild S, eds. Metabolic Syndrome. Chichester: John Wiley and Sons, 2005: 279-305.
21. Ahmed MH BC. Metabolic syndrome, diabetes and CHD risk. In: Packard CJ, ed. The Year in Lipid Disorders. Oxford: Clinical Publishing, 2007: 3-26.
22. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos Nutrition and Liver Study. Hepatology 2005; 42: 44-52.
23. Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132: 112-117.
24. Rocha R, Cotrim HP, Carvalho FM, Siqueira AC, Braga H, Freitas LA. Body mass index and waist circumference in non-alcoholic fatty liver disease. J Hum Nutr Diet 2005; 18: 365-370.
25. Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002; 35: 367-372.
26. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-379.
27. Sung KC, Jeong WS, Wild SH, Byrne CD. Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for Type2 diabetes. Diabetes Care 2012; 35: 717-722.
28. Gastaldelli A, Kozakova M, Hojlund K, Flyvbjerg A, Favuzzi A, Mitrakou A et al. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 2009; 49: 1537-1544.
29. Yun KE, Shin CY, Yoon YS, Park HS. Elevated alanine aminotransferase levels predict mortality from cardiovascular disease and diabetes in Koreans. Atherosclerosis 2009; 205: 533-537.
30. Targher G, Bertolini L, Rodella S, Tessari R, Zenari L, Lippi G et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type2 diabetic patients. Diabetes Care 2007; 30: 2119-2121.
31. Soderberg C, Stal P, Askling J, Glaumann H, Lindberg G, Marmur J et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010; 51: 595-602.
32. Schindhelm RK, Dekker JM, Nijpels G, Bouter LM, Stehouwer CD, Heine RJ et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 2007; 191: 391-396.
33. Ruttmann E, Brant LJ, Concin H, Diem G, Rapp K, Ulmer H. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163944 Austrian adults. Circulation 2005; 112: 2130-2137.
34. Lee DH, Silventoinen K, Hu G, Jacobs DR Jr, Jousilahti P, Sundvall J et al. Serum gamma-glutamyltransferase predicts non-fatal myocardial infarction and fatal coronary heart disease among 28838 middle-aged men and women. Eur Heart J 2006; 27: 2170-2176.
35. Haring R, Wallaschofski H, Nauck M, Dorr M, Baumeister SE, Volzke H. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. Hepatology 2009; 50: 1403-1411.
36. Hamaguchi M, Kojima T, Takeda N, Nagata C, Takeda J, Sarui H et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 2007; 13: 1579-1584.
37. Fraser A, Harris R, Sattar N, Ebrahim S, Smith GD, Lawlor DA. Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and Meta-Analysis. Arterioscler Thromb Vasc Biol 2007; 27: 2729-2735.
38. Dunn W, Xu R, Wingard DL, Rogers C, Angulo P, Younossi ZM et al. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol 2008; 103: 2263-2271.
39. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-121.
40. Ahmed MH, Byrne CD. Current treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab 2009; 11: 188-195.
41. Perseghin G. The role of non-alcoholic fatty liver disease in cardiovascular disease. Dig Dis 2010; 28: 210-213.
42. Bhala N, Angulo P, van der Poorten D, Lee E, Hui JM, Saracco G et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011; 54: 1208-1216.
43. Sung KC, Ryan MC, Wilson AM. The severity of nonalcoholic fatty liver disease is associated with increased cardiovascular risk in a large cohort of non-obese Asian subjects. Atherosclerosis 2009; 203: 581-586.
44. McKimmie RL, Daniel KR, Carr JJ, Bowden DW, Freedman BI, Register TC et al. Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type2 diabetes: the Diabetes Heart Study. Am J Gastroenterol 2008; 103: 3029-3035.
45. Dam-Larsen S, Becker U, Franzmann MB, Larsen K, Christoffersen P, Bendtsen F. Final results of a long-term, clinical follow-up in fatty liver patients. Scand J Gastroenterol 2009; 44: 1236-1243.
46. Alkhouri N, Tamimi TA, Yerian L, Lopez R, Zein NN, Feldstein AE. The inflamed liver and atherosclerosis: a link between histologic severity of nonalcoholic fatty liver disease and increased cardiovascular risk. Dig Dis Sci 2010; 55: 2644-2650.
47. Ramilli S, Pretolani S, Muscari A, Pacelli B, Arienti V. Carotid lesions in outpatients with nonalcoholic fatty liver disease. World J Gastroenterol 2009; 15: 4770-4774.
48. McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 2004; 8: 521-533, viii.
49. Tolman KG, Fonseca V, Tan MH, Dalpiaz A. Narrative review: hepatobiliary disease in type2 diabetes mellitus. Ann Intern Med 2004; 141: 946-956.
50. Jousilahti P, Rastenyte D, Tuomilehto J. Serum gamma-glutamyl transferase, self-reported alcohol drinking, and the risk of stroke. Stroke 2000; 31: 1851-1855.
51. Wannamethee G, Ebrahim S, Shaper AG. Gamma-glutamyltransferase: determinants and association with mortality from ischemic heart disease and all causes. Am J Epidemiol 1995; 142: 699-708.
52. Schindhelm RK, Dekker JM, Nijpels G, Bouter LM, Stehouwer CD, Heine RJ et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 2007; 191: 391-396.
53. Monami M, Bardini G, Lamanna C, Pala L, Cresci B, Francesconi P et al. Liver enzymes and risk of diabetes and cardiovascular disease: results of the Firenze Bagno a Ripoli (FIBAR) study. Metabolism 2008; 57: 387-392.
54. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type2 diabetic patients. Diabetes Care 2007; 30: 1212-1218.
55. Targher G, Bertolini L, Poli F, Rodella S, Scala L, Tessari R et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type2 diabetic patients. Diabetes 2005; 54: 3541-3546.
56. Ahmed MH, Byrne CD. Ezetimibe as a potential treatment for non-alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation? Drug Discov Today 2010; 15: 590-595.
57. Calder PC. The relationship between the fatty acid composition of immune cells and their function. Prostaglandins Leukot Essent Fatty Acids 2008; 79: 101-108.
58. Riediger ND, Othman RA, Suh M, Moghadasian MH. A systemic review of the roles of n-3 fatty acids in health and disease. J Am Diet Assoc 2009; 109: 668-679.
59. Calder PC, Yaqoob P. Understanding omega-3 polyunsaturated fatty acids. Postgrad Med 2009; 121: 148-157.
60. Kotronen A, Yki-Jarvinen H. Fatty liver. A novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008; 28: 27-38.
61. Araya J, Rodrigo R, Videla LA, Thielemann L, Orellana M, Pettinelli P et al. Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci (Lond) 2004; 106: 635-643.
62. Reddy JK. Nonalcoholic steatosis and steatohepatitis. III. Peroxisomal β-oxidation, PPAR-α, and steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2001; 281: G1333-G1339.
63. Clarke SD. Polyunsaturated fatty acid regulation of gene transcription: a molecular mechanism to improve the metabolic syndrome. J Nutr 2001; 131: 1129-1132.
64. Clarke SD. Nonalcoholic steatosis and steatohepatitis. I. Molecular mechanism for polyunsaturated fatty acid regulation of gene transcription. Am J Physiol Gastrointest Liver Physiol 2001; 281: G865-G869.
65. Clarke SD. The multi-dimensional regulation of gene expression by fatty acids: polyunsaturated fats as nutrient sensors. Curr Opin Lipidol 2004; 15: 13-18.